UCSF to attack HIV at molecular level with new center and $7 million in state funds

September 20, 1999

Funded by a six-year, $7 million grant from the State of California, the new project is named the UCSF California AIDS Research Center.

The Center is designed to coordinate basic and clinical science investigation through a unified, single program directed at gaining new understanding at the molecular level of the biological factors that facilitate and inhibit HIV transmission, how to prevent HIV infection, and how to delay progression of disease once a person is infected.

This is the first time UCSF has had a single center focusing on this key area of research.

"This crucial funding from the state will fill a critical gap in UCSF's research portfolio and lead to improved vaccine concepts and better therapies for persons already infected with HIV. This grant brings together laboratory, clinical, and public health scientists in a new way," said John Greenspan, BDS, Ph.D., Center director and chair of the UCSF Department of Stomatology.

He also emphasized that the new organization will combine the next generation of HIV research with the strength of extensive, ongoing work by UCSF AIDS specialists.

"AIDS and HIV are not going away, so in addition to supporting four target areas, the Center will serve as a breeding ground for new ideas that build on the expertise and long experience of our team in AIDS work. One of our goals is to respond in dynamic fashion to the needs of HIV research by stimulating the development of pilot projects that will test new theories," Greenspan said.

"Another goal is to end the HIV epidemic in California, and key support comes from the University of California system," he added. The new Center will receive state monies through the UC University-wide AIDS Research Program, an entity formed in the mid-1980s to administer state funds for quality AIDS research.

Deputy directors of the new UCSF Center are Paul Volberding, MD, an expert in HIV/AIDS clinical treatment, and Margaret Chesney, PhD, a leader in behavioral prevention efforts, both of whom are recognized internationally.

Research projects led by UCSF AIDS specialists will target four major areas: transmission of drug-resistant HIV, molecular and cellular interactions in HIV infection, molecular mechanisms of HIV therapies, and resistance against HIV infection through a vaccine.

One of the projects will focus on animal testing of a new vaccine concept, while the others will investigate how to begin to develop vaccines against HIV to work both in those who are infected and in those who are uninfected.

UCSF was one of the first institutions in the world to document the fact that drug-resistant HIV could be transmitted. Researchers now are planning to take the next step. "We need to find out at this early stage whether or not there is a lot of resistant HIV being spread in the community," said Robert Grant, MD, MPH, director of the Gladstone/UCSF Virology Core Laboratory, who will oversee this research.

One of the most important areas of HIV/AIDS research is vaccine development, emphasized Thomas J. Coates, PhD, executive director of the UCSF AIDS Research Institute (UCSF ARI).

"Some might wonder why we need more basic and applied research on vaccines when there are trials already of vaccines in the field. What we need right now are more and better vaccine concepts, and we need to be testing as many of them simultaneously as possible. We still haven't found the 'magic bullet,' and we' re probably not going to find it soon. The vaccines being tested now may or may not prove to be useful against HIV. We need to keep the pipeline running with new ideas and products if we're going to find a way to stop HIV and AIDS," he said.

The UCSF ARI is a campuswide enterprise without walls that encompasses all UCSF AIDS programs under a single umbrella and includes close to 1,000 investigators.

A leading institution in the fight against HIV/AIDS since the beginning of the epidemic in the early1980s, UCSF is known throughout the world as the model for studying the disease in all areas-basic science, treatment approaches, prevention strategies, and policy issues.

Greenspan and Volberding are two UCSF faculty who have been with the UCSF AIDS program from its earliest days when the first patients were diagnosed, and they both emphasized that they "plan to be here not only to help the epidemic end, but also to see it end."
-end-


University of California - San Francisco

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.